Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06665971 · ClinicalTrials.gov registry record · Phase 4
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
A Phase 4 study of Eosinophilic Esophagitis (EoE), sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06665971: Recruiting Phase 4 study of Eosinophilic Esophagitis (EoE), sponsored by University of California, San Diego.
NCT06665971 is a Phase 4 study of Eosinophilic Esophagitis (EoE) that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 30 participants, below the 123-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06665971, a Phase 4 study of Eosinophilic Esophagitis (EoE), is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Participants with EoE have dysfunction of the muscle of the esophagus (impaired peristalsis) that is not favorable for the transport function. Main question this study aims to answer is: Whether Dupilumab helps improve muscle activity of the esophagus in participants with EOE? Participants will: Take Dupilumab every week for 12 weeks. Visit the clinic before and after starting the medication. Keep a diary of symptoms.
Primary Outcome
To see if there is an improvement in the longitudinal muscle dysfunction - increase in the muscle thickness (difference between baseline and at the peak of swallow-induced esophageal contraction), and peak muscle thickness at the peak of circular muscle contraction, measured in millimeters will be recorded. The investigators will make paired observation in each participant, i.e., before and after treatment with Dupilumab, and perform paired t test statistics.
Conditions Studied
Interventions
- DRUG Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Study Locations (1)
California
- University of California San Diego (UCSD) Health Medical center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-11-10 |
| Est. Completion | 2026-11-14 |
| Phase | Phase 4 |
What NCT06665971 shows while recruiting
NCT06665971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 123-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Eosinophilic Esophagitis (EoE) appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] is the first listed.
NCT06665971 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06665971 about?
NCT06665971 is a clinical study titled "Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)". The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Part...
What is the current status of trial NCT06665971?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-11-10. Estimated completion is 2026-11-14.
What conditions does trial NCT06665971 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis (EoE).
What interventions are being tested in trial NCT06665971?
The interventions under investigation include: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] (DRUG).
Who is sponsoring clinical trial NCT06665971?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06665971 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis (EoE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06665971's enrollment target sits among peer trials
30 9th of 10 higher than 1 of 10 other Eosinophilic Esophagitis (EoE) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis (EoE) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surface EMG Testing on Swallowing in EoE Patients
RECRUITING
-
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
RECRUITING
-
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
RECRUITING · Phase 3
-
Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
RECRUITING
-
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI